The Gram-positive bacterium Lactococcus lactis produces two distinct multidrug transporters, designated LmrA and LmrP, that both confer resistance to a wide variety of cationic lipophilic cytotoxic compounds as well as to many clinically relevant antibiotics. While LmrP is a proton/drug antiporter that belongs to the major facilitator superfamily of secondary transporters, LmrA is an ATP-dependent primary transporter that belongs to the ATP-binding cassette superfamily of transport proteins. Both LmrA and LmrP function as ''hydrophobic vacuum cleaners'' by excreting lipophilic cationic compounds from the inner leaflet of the membrane directly into the external water phase. LmrA is both functionally and structurally homologous to the human multidrug transporter P-glycoprotein. LmrA is a half ABC transporter that is functional as a homodimer, consistent with the general four-domain organization of ABC transporters, and is proposed to mediate drug transport by an alternating two-site transport mechanism. D
Introduction
Microorganisms are almost continuously exposed to numerous environmental toxins ranging from natural compounds (e.g. plant alkaloids), peptides (e.g. bacteriocins) and noxious metabolic products (e.g. bile salts and fatty acids in the case of enteric bacteria), to industrially produced chemicals such as organic solvents and antibiotics. Microorganisms have developed several mechanisms to resist the toxic effects of antimicrobial agents, and drug-resistant pathogens are on the rise. A major mechanism of resistance involves the active extrusion of antimicrobials from the cell by drug transport systems. Some of these drug excretion systems mediate the extrusion of a given drug or class of drugs. In contrast to these specific drug resistance (SDR) transporters, the so-called multidrug resistance (MDR) transporters can handle a wide variety of structurally unrelated compounds. On the basis of bioenergetic and structural criteria, multidrug transporters can be divided into two major classes: (i) secondary transporters that are driven by a proton or sodium motive force and (ii) ATP-binding cassette (ABC) primary transporters, which use the hydrolysis of ATP to fuel transport (for a recent review, see Ref. [1] ).
In the Gram-positive bacterium Lactococcus lactis, an organism broadly used in food manufacturing, two distinct MDR transporters mediate resistance to toxic hydrophobic cations and antibiotics. One MDR transporter, designated LmrP, is a proton/drug antiport system, while the second MDR transporter, designated LmrA, is an ATP-dependent primary ABC transporter (Fig. 1) . Hence, LmrP and LmrA exemplify the two major classes of multidrug transporters found in bacteria. Growth of L. lactis in the presence of increasing concentrations of toxic compounds results in an increase in energy-dependent drug-extrusion, suggesting that the expression of these transporters is upregulated [2] . When one of the transporters is deleted, the expression of the other MDR transporter is increased. So far, attempts to delete both MDR transporter genes have been unsuccessful, emphasizing the important role of these proteins for the viability of L. lactis, even in media to which no toxic compounds have been added. In addition to LmrA and LmrP, which are involved in the excretion of lipophilic cations, L. lactis also possesses two MDR transporters that mediate the extrusion of anionic antimicrobial compounds [3, 4] . The genes encoding the latter two MDR transporters have not been cloned yet, but with the availability of the L. lactis genome sequence these genes will soon be identified. This review summarizes the existing data only of the two well-studied multidrug transporters LmrA and LmrP.
The secondary MDR transporter LmrP
LmrP is a 408-amino acid-long membrane protein that belongs to the major facilitator superfamily (MFS) of secondary transporters. Based on its hydrophobicity profile, the ''positive inside rule,'' and the homology for better characterized MFS transporters, a secondary structure model was constructed for LmrP [5] . This model predicts that LmrP contains 12 transmembrane segments (TMS), linked by cytosolic and external loop regions, with the N-and Ctermini facing the cytoplasm (Fig. 2 ). LmrP has a broad substrate specificity and can handle a wide variety of lipophilic cationic toxins such as ethidium, rhodamine 123, daunomycin, and tetraphenylphosphonium (TPP + ) [2, 5, 6] . Interestingly, the transporter also confers resistance to several broad-spectrum antibiotics belonging to the classes of lincosamides, macrolides, streptogramins and tetracyclines [7] . Transport experiments in intact cells and in inside-out membrane vesicles demonstrated that extrusion of cationic drugs by LmrP is driven by both the membrane potential and the transmembrane proton gradient, indicating that LmrP mediates electrogenic nH + /drug (n z 2) antiport [5, 6, 8] . LmrP can be functionally overexpressed in L. lactis using the tightly regulated, nisin-controlled expression (NICE) system [9] . Proton motive force (pmf)-dependent drug efflux by LmrP in inside-out membrane vesicles was inhibited by low concentrations of detergents, such as Triton X-100, Triton X-114, and Tween 80, that did not affect the magnitude or composition of the pmf. This finding restricted the range of compounds that could be used for the solubilization and reconstitution of the protein, because low concentrations of detergent are retained in proteoliposomes. However, dodecyl maltoside did not modulate the activity of LmrP, and this detergent was therefore used to solubilize and functionally reconstitute the protein in dodecyl maltoside-destabilized, preformed liposomes composed of Escherichia coli phospholipids and egg phosphatidyl choline [9] . Purified and reconstituted LmrP mediated the transport of multiple drugs in response to an artificially imposed pH gradient, demonstrating that this efflux pump functions independent of accessory proteins [9] .
Most drugs that interact with multidrug transporters such as LmrP readily intercalate into the lipid bilayer due to their high hydrophobicity and amphiphilic nature. Drug extrusion by LmrP (and also by LmrA, see below) occurs from the membrane, rather than from the cytoplasm. This is evident from the observation that the non-fluorescent compound BCECF-AM is excreted from LmrP-producing cells prior to hydrolysis into the fluorescent cellular indicator BCECF by intracellular esterases [8] . The most convincing evidence for drug efflux from the membrane to the aqueous phase is provided by the kinetics of TMA-DPH transport by LmrP and LmrA [8, 10] . TMA-DPH partitions readily into the lipid bilayer. It is strongly fluorescent when partitioned into the membrane but essentially non-fluorescent in an aqueous environment, which makes it possible to fluorimetrically follow the partitioning of TMA-DPH into the lipid bilayer. The increase in fluorescence intensity due to the partitioning of TMA-DPH into the phospholipid bilayer was found to be a biphasic process (Fig. 3) [8] . A rapid process that reflects the fast entry (1 -2 s) of TMA-DPH into the outer leaflet of the phospholipid bilayer is followed by a slower (several minutes) transbilayer movement from the outer to the inner leaflet of the membrane. Energization of intact cells by the addition of glucose revealed that the initial rate of extrusion of TMA-DPH, monitored as a decrease in fluorescence over time, increased with an increasing concentration of TMA-DPH in the inner leaflet of the membrane (Fig. 3A ) [8] . The extent of extrusion never exceeded the amount of TMA-DPH present in the inner leaflet, indicating that the probe cannot be extruded from the outer leaflet of the cytoplasmic membrane. When similar experiments were done with inside-out membrane vesicles, with the inner leaflet now immediately accessible to drug molecules, the situation was significantly different (Fig. 3B ). Upon addition of TMA-DPH to the membrane vesicle suspension, TMA-DPH rapidly intercalates into the exposed leaflet of the membrane, resulting in a maximum concentration of TMA-DPH in this leaflet. Upon energization maximal rates of TMA-DPH extrusion were observed at any moment after addition of TMA-DPH and the extent of extrusion, in contrast to intact cells, now exceeded the amount of TMA-DPH present in the internal leaflet of inside-out vesicles (Fig. 3B ). These observations strongly indicate that TMA-DPH is recognized as substrate only after partitioning into the normal inner leaflet of the cellular membrane, and is directly transported to the aqueous environment as observed by the decrease in fluorescence. These observations indicate that LmrP functions by a vacuum cleaner mechanism (Fig. 4) [10] .
Interestingly, the kinetic analysis of inhibition of LmrPmediated Hoechst 33342 transport by drug molecules revealed competitive inhibition by quinine and verapamil, non-competitive inhibition by nicardipin and vinblastin, and uncompetitive inhibition by TPP + [6] . These findings are indicative for the presence of multiple drug interaction sites in this multidrug transport protein. Understanding the molecular basis of multidrug recognition by LmrP is a major goal. According to the predicted membrane topology (Fig. 2) , the . The kinetics of TMA-DPH fluorescence development upon the addition to membranes is biphasic. The initial fast phase reflects probe partitioning in the outer leaflet of the membrane, while the second slower phase is due to the transbilayer movement of TMA-DPH into the inner leaflet of the membrane. Cells were energized with 25 mM of glucose at 0, 5 and 15 min after the addition of 100 nM of TMA-DPH. In cells, the initial rate of TMA-DPH extrusion increases in the course of probe flipping from the outer to inner leaflet of the membrane, whereas the steady state TMA-DPH fluorescence remains the same (A). The ISO membrane vesicles were energized with 10 mM D-lactate at 0, 2, 5 and 10 min after the addition of 100 nM TMA-DPH. In the vesicles, the initial transport rates were identical and independent of the partitioning of TMA-DPH into the inner leaflet of the inverted membrane vesicles (B). The steady state fluorescence in this experiment increased along with the partitioning of TMA-DPH into the internal leaflet of the inverted membranes. Data obtained from Ref. [8] . Fig. 4 . Vacuum cleaner mechanism of drug transport across the cytoplasmic membrane. The lipophilic cytotoxic compounds intercalate rapidly in the outer leaflet of the membrane. Subsequently, the compound flips slowly from the outer leaflet to the inner leaflet of the membrane from where they can diffuse into the cytosol. The MDR pump interacts with the cytotoxic compound in the inner leaflet of the membrane and excretes the compound by an energy-dependent process directly into the external water phase.
putative TMS of LmrP are very hydrophobic and contain three charged residues, D142, E327, and E388, which are located in TMS V, X, and XII, respectively. Cysteine scanning mutagenesis, in combination with thiol chemistry, of all acidic residues in LmrP provided strong evidence that except for D142, E327, and E388, no other negatively charged residues are present in the membrane-embedded domain of LmrP. Site-directed mutagenesis and transport experiments revealed that the negative charges at positions 142 and 327 are important for the recognition of some cationic drugs by LmrP [26] .
The primary ABC-type MDR transporter LmrA
From the energetics in vivo it is clear that the chromosomally located lmrA gene encodes an ATP-coupled primary efflux pump [2] . Most importantly, LmrA is inhibited by ortho-vanadate, an inhibitor of ABC transporters and Ptype ATPases, but not upon dissipation of the pmf [2, 10] . In vitro, isolated membrane vesicles and proteoliposomes, in which purified LmrA was reconstituted, were employed to prove that transport of multiple drugs was LmrA-and ATPdependent [11, 12] . Hydropathy analysis of the 590 amino acid LmrA protein suggests a putative topology of six membrane spanning regions (putative a-helices) in the amino-terminal hydrophobic domain, followed by a large hydrophilic domain containing the ATP-binding site [11] (Fig. 5) . Recent studies involving cysteine scanning mutagenesis (G.J. Poelarends and W.N. Konings, unpublished results) and Attenuated Total Reflection Fourier Transform Infrared Spectroscopy (ATR-FTIR) [13] have provided strong experimental evidence that the membrane spanning regions of LmrA are indeed a-helices. The nucleotide binding domain (NBD) of LmrA contains features diagnostic of an ABC-type ATPase, such as the ABC signature sequence and the Walker A and B motifs [11] . In view of the general four-domain organization of ABC transporters, consisting of two transmembrane domains (TMDs) and two NBDs [14] , LmrA appears to be a half transporter. This suggests that LmrA might function as a homodimer to form a full transporter with four core domains. Several lines of evidence convincingly demonstrated that this is indeed the case (reviewed in Ref. [15] ).
The 65 kDa LmrA protein shares significant sequence similarity with members of the P-glycoprotein subfamily of ABC transporters, most notably the human MDR P-glycoprotein. LmrA and each half of P-glycoprotein (MDR1) share 34% identical residues and an additional 16% of conservative substitutions [11] . The sequence conservation in the TMD of LmrA includes particular regions (e.g. the region comprising transmembrane helices 5 and 6), which have been implicated as being involved in drug binding by MDR1 [16] . Interestingly, LmrA shares 28% overall sequence identity with the lipid flippase MsbA from E. coli, the structure of which was recently determined by X-ray crystallography to a resolution of 4.5 Å [17] .
As pointed out for LmrP, LmrA was also shown to function as a ''hydrophobic vacuum cleaner,'' which extrudes toxic lipophilic compounds from the inner leaflet of the lipid bilayer directly into the external water phase [10] . Its classification as a multidrug transporter is evident from its currently known spectrum of substrates. LmrA substrates include anticancer drugs such as vinca alkaloids (vinblastine, vincristine) and anthracyclines (daunomycin, doxorubicin), or cytotoxic agents such as antimicrotubule drugs (colchicine) and DNA intercalators (ethidium bromide), or toxic peptides (valinomycin, nigericin), fluorescent membrane probes (Hoechst 33342, diphenyl-hexatriene), and fluorescent dyes such as rhodamine 6G and rhodamine 123 [11, 12, 15, 18, 19] . LmrA modulators (i.e. compounds that reverse LmrA-mediated multidrug resistance) are also structurally unrelated to each other and include calcium channel blockers (e.g. verapamil), 1,4-dihydropyridines (e.g. nicardipine), indolizine sulfones (e.g. SR33557), antimalarials (e.g. quinine and quinidine), immunosuppressants (e.g. cyclosporin A), and the Rauwolfia alkaloid reserpine [11, 19] .
To address the role of LmrA in antibiotic resistance, the lmrA gene was expressed in E. coli strain CS1562, which is hypersensitive to drugs due to a deficiency of the TolC porin. LmrA producing cells showed an increased resistance to 17 out of 21 clinically most used antibiotics, including broadspectrum antibiotics belonging to the classes of aminoglycosides, lincosamides, macrolides, quinolones, streptogramins and tetracyclines (Table 1) [20] . This further demonstrates the remarkable broad substrate specificity of LmrA. In addition, it has recently been demonstrated that purified and reconstituted LmrA can also transport phospholipids [12] .
The functional similarity between bacterial LmrA and human P-glycoprotein is exemplified by their currently known spectrum of substrates, consisting mainly of hydrophobic cations. Another interesting aspect is that LmrA, when overexpressed in insect and human lung fibroblast cells, is able to functionally complement P-glycoprotein [21] . Surprisingly, LmrA was targeted to the plasma membrane and conferred typical multidrug resistance on the human cells. The pharmacological characteristics of LmrA and P-glycoprotein expressed in lung fibroblast cells were very similar [21] . This remarkable conservation of function between these two ABC-type multidrug transporters implies a common overall structure and transport mechanism.
Several lines of evidence convincingly demonstrated that each homodimer of LmrA contains a low-affinity drugbinding site that is allosterically coupled to a high-affinity drug-binding site [22] . The dissociation constants for the two vinblastine-binding sites are approximately 150 and 30 nM vinblastine, respectively. These drug-binding sites appear to be directly involved in drug transport as shown by the reciprocal stimulation of LmrA-mediated vinblastine and Hoechst 33342 transport at low drug concentrations, and reciprocal inhibition at high drug concentrations [22] . The obligatory link between the drug-binding and catalytic cycles has been shown by vanadate-trapping experiments [22] . It was found that of the two vinblastine-binding sites accessible in the LmrA transporter, only the low-affinity vinblastinebinding site is accessible in the vanadate-trapped transition state conformation of LmrA. In addition, specific photoaffinity labelling of the vanadate-trapped LmrA transporter with [
3 H]-APDA, a drug that can be transported by LmrA, was obtained in right-side-out membrane vesicles, but not in inside-out membrane vesicles, demonstrating that the lowaffinity drug-binding site is exposed to the outside (extracellular) surface of the cell membrane. The vanadate-trapped conformation of LmrA, with a single low-affinity drugbinding site exposed to the extracellular surface, is consistent with the hypothesis that an ATP hydrolysis-induced conformational change moves a high-affinity drug-binding site from the inside of the membrane to the outside with a concomitant change to a low affinity site [22, 23] . Indeed, conformational changes in LmrA upon hydrolysis of ATP have been detected by ATR-FTIR spectroscopy [24] .
The substrate-binding data obtained with (vanadate-trapped) LmrA, when combined with the alternating catalytic site model, in which the ABC domains of P-glycoprotein act alternately to hydrolyze ATP [25] , led to the proposition of an alternating two-site transport model [22, 23] (Fig. 6) . This model predicts that in a complete drug transport cycle, each monomer of the LmrA dimer alternates its drug-binding site from high affinity to occluded state to low affinity and back to high affinity. The affinities of the binding-sites in the Fig. 6 . Alternating two-site transport model. Rectangles represent the transmembrane domains of LmrA. Circles, squares and hexagons represent different conformations of the NBDs. The ATP-bound (circle) state is associated with a high-affinity drug-binding site on the inside of the transporter. The ADP-bound (square) state is associated with a low-affinity drug-binding site on the outside of the transporter. The ADP-Pi (hexagonal) state is associated with an occluded drug-binding site, and represents the ADP/vanadate-trapped form of the ABC domain. According to the model, the transporter oscillates between two configurations, each containing a high affinity, inside-facing, transport-competent drug-binding site, and a low affinity, outside-facing drug-release site. The ATP-dependent interconversion of one configuration into the other proceeds via a catalytic transition state conformation in which the transport-competent site is occluded. monomers alternate: when the drug-binding site in one monomer is in the high affinity state the binding site in the other monomer is in a low affinity state and vice versa. Hence, this process is called ''an alternating two-site mechanism''. Such a scenario implies that both halves of the apparently symmetric LmrA transporter are able to act asymmetrically. However, it is presently not clear whether the binding sites are present in separate TMDs or at the interface between TMDs.
Conclusions and perspectives
Studies on bacterial MDR transporters are relevant because during the past years it has become evident that MDR activities are involved in the ongoing emergence of antibiotic resistance in pathogenic bacteria. Although L. lactis is considered to be non-pathogenic and safe to use in starter cultures for cheese production, the exceptionally broad antibiotic specificity of LmrP and LmrA, the possible transfer of the lmrP and lmrA genes to other bacteria in food or the digestive tract, and the presence of homologues in pathogenic microorganisms [15, 18] , provide a serious threat to the efficacy of valuable antibiotics. In addition, LmrA is able to complement the human MDR P-glycoprotein, supporting the clinical and academic value of studying these bacterial proteins.
Transport of cytotoxic drugs from the cytoplasmic leaflet of the membrane appears to be the most efficient way in which MDR transporters can prevent toxic compounds from entering the cytoplasm. Drug molecules reaching the cell rapidly insert into the outer leaflet of the membrane, but flipping of the drug molecules from the outer to inner leaflet is slow and the rate-limiting step in entry. LmrP and LmrA are able to transport drug molecules from the inner leaflet back into the external medium, counteracting the rate-limiting step in drug entry. If these transporters would transport drugs from the outer leaflet of the membrane, they would probably not be able to compete with the high rate at which drug molecules enter this leaflet. Drug molecules would ''escape'' into the inner leaflet and subsequently enter the cytoplasm.
